Subscribe Login
A-Brands

J&J Raises Forecast After Quarterly Profit Beats Estimates

Johnson & Johnson raised its full-year profit forecast and beat analysts' estimates for quarterly earnings on Thursday as strength in its pharmaceuticals unit cushioned a steep fall in sales of its medical devices due to the COVID-19 pandemic.

Sales in the healthcare conglomerate's medical devices unit tumbled 33.9% in the second quarter as hospitals and patients delayed non-urgent procedures like hip and knee replacements.

But its large pharmaceuticals unit offset the slump, rising 2.1%, helped by strong demand for Stelara, used to treat Crohn's disease and plaque psoriasis, and cancer drug Darzalex.

Raises Full-Year Profit Forecast 

The company raised its full-year adjusted profit forecast to $7.75 to $7.95 per share, from its prior estimate of $7.50 to $7.90 per share.

J&J's total sales fell 10.8% to $18.34 billion, but beat estimates of $17.61 billion, according to IBES data from Refinitiv.

The company, which is set to begin human trials of its experimental coronavirus vaccine this month, reported net earnings of $3.63 billion, or $1.36 per share, down from $5.61 billion, or $2.08 per share, a year earlier.

Excluding items, J&J earned $1.67 per share, beating the average analyst estimate of $1.49 per share.

News by Reuters edited by Donna Ahern, Checkout. Click subscribe to sign up for the Checkout print edition.

Stay Connected With Our Weekly Newsletter

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our Terms & Conditions and Privacy Policy
Enjoy unlimited digital access for 30 days
Enjoy full access to Checkout Magazine, our weekly email news digest, access to all website and app content, and the latest digital magazine for a full 30 days.
Enjoy unlimited digital access for 30 days
Enjoy unlimited digital access for 30 days
Enjoy full access to Checkout Magazine, our weekly email news digest, access to all website and app content, and the latest digital magazine for a full 30 days.
Enjoy unlimited digital access for 30 days